Teva Pharmaceutical Industries Limited (TEV) — Cash Flow-to-Debt Ratio
Teva Pharmaceutical Industries Limited (TEV) has a Cash Flow-to-Debt Ratio of 0.00x as of March 2026, meaning its operating cash flow of €-40.00 Million could theoretically repay 0% of its total liabilities (€31.81 Billion) in one year. See Teva Pharmaceutical Industries Limited leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Teva Pharmaceutical Industries Limited Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Teva Pharmaceutical Industries Limited across 11 annual periods. For the full cash flow conversion analysis, see how efficiently does Teva Pharmaceutical Industries Limited generate cash.
Annual Cash Flow-to-Debt Ratio for Teva Pharmaceutical Industries Limited (2015–2025)
Year-by-year debt coverage analysis for Teva Pharmaceutical Industries Limited. Check earnings quality score of Teva Pharmaceutical Industries Limited to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.05x | €1.65 Billion | €32.83 Billion | ▲ +35.3% |
| 2024 | 0.04x | €1.25 Billion | €33.61 Billion | ▲ +13.4% |
| 2023 | 0.03x | €1.16 Billion | €35.35 Billion | ▼ -27.3% |
| 2022 | 0.05x | €1.59 Billion | €35.31 Billion | ▲ +105.5% |
| 2021 | 0.02x | €798.00 Million | €36.42 Billion | ▼ -28.7% |
| 2020 | 0.03x | €1.22 Billion | €39.58 Billion | ▲ +74.2% |
| 2019 | 0.02x | €748.00 Million | €42.41 Billion | ▼ -67.6% |
| 2018 | 0.05x | €2.45 Billion | €44.89 Billion | ▲ +27.0% |
| 2017 | 0.04x | €2.23 Billion | €51.87 Billion | ▼ -36.2% |
| 2016 | 0.07x | €3.89 Billion | €57.90 Billion | ▼ -70.5% |
| 2015 | 0.23x | €5.54 Billion | €24.31 Billion | — |